Table 2:

Qualitative assessment of patients with brain tumors: intraindividual comparison of 0.1-mmol/kg gadobenate and 0.1-mmol/kg gadoterate^a

Diagnostic Information End Point	Reader	Gadobenate Preferred	No Difference	Gadoterate Preferred	Significance (P Value)b	3-Reader Agreement κ Value (% Agreement)
Global diagnostic preference	1	31 (49.2%)	31 (49.2%)	1 (1.6%)	<.0001	0.273 (50.8%)
	2	51 (82.3%)	9 (14.5%)	2 (3.2%)	<.0001
	3	43 (69.4%)	17 (27.4%)	2 (3.2%)	<.0001
Lesion-border delineation	1	29 (46.0%)	33 (52.4%)	1 (1.6%)	<.0001	0.271 (44.3%)
	2	34 (54.8%)	27 (43.5%)	1 (1.6%)	<.0001
	3	25 (40.3%)	35 (56.5%)	2 (3.2%)	<.0001
Definition of disease extent	1	15 (23.8%)	48 (76.2%)	0	<.0001	0.286 (57.4%)
	2	18 (29.0%)	43 (69.4%)	1 (1.6%)	<.0001
	3	15 (24.2%)	45 (72.6%)	2 (3.2%)	.0023
Visualization of lesion internal morphology	1	10 (15.9%)	53 (84.2%)	0	.002	0.215 (54.1%)
	2	14 (22.6%)	48 (77.4%)	0	.0001
	3	23 (37.1%)	38 (61.3%)	1 (1.6%)	<.0001
Lesion contrast enhancement	1	31 (49.2%)	31 (49.2%)	1 (1.6%)	<.0001	0.249 (49.2%)
	2	51 (82.3%)	9 (14.5%)	2 (3.2%)	<.0001
	3	43 (69.4%)	17 (27.4%)	2 (3.2%)	<.0001

^aComparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n = 63 for reader 1, n = 62 for readers 2 and 3. Numbers in parentheses, except where noted, represent proportions of patients.

^bWilcoxon signed rank test.